四烯丙基溴化铵 | 6919-32-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 四烯丙基溴化铵
• 英文名称: Tetraprop-2-enylazanium
• 英文别名: tetrakis(prop-2-enyl)azanium
• CAS: 6919-32-0
• 化学式: C12H20N+
• 分子量: 178.29
• InChiKey: SAJMIAZRBZSBQM-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX ANTAGONISTES DE LA GLUTAMINE ET LEURS UTILISATIONS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2019071110A1

  公开（公告）日：2019-04-11

  Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

  谷氨酰胺拮抗剂及其用于治疗肿瘤、免疫和神经系统疾病的方法已被披露。还披露了治疗肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。还披露了增强免疫检查点抑制剂效果的方法，使受试者对免疫检查点抑制剂产生反应，或减少免疫检查点抑制剂的毒性或剂量或治疗次数的方法，包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量，以及免疫检查点抑制剂。还披露了治疗对检查点抑制剂疗法无效的肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。
• Preparation of Saturated Ketone Morphinan Compounds Having Low Metal Content
  申请人：Jiang Tao

  公开号：US20110269963A1

  公开（公告）日：2011-11-03

  The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers.

  本发明提供了一种从含有烯丙醇环基团的吗啡骨架制备饱和酮吗啡类化合物的方法，其中最终产品的金属含量较低。具体而言，该发明提供了利用过渡金属催化的异构化反应和随后利用金属捕集剂去除过渡金属的方法。
• Pharmaceutical Process and Intermediates
  申请人：McKeever Benedict

  公开号：US20150175639A1

  公开（公告）日：2015-06-25

  The present disclosure provides for processes and intermediates in the large-scale manufacture of the compound of formula (I) or hydrates thereof.

  本公开提供了用于大规模制造化合物I的工艺和中间体，或其水合物。
• Immobilized iminophosphatranes useful for transesterification
  申请人：Verkade G. John

  公开号：US20050176978A1

  公开（公告）日：2005-08-11

  The present invention provides a method for transesterifying an ester, comprising combining the ester, a C 1 -C 3 alcohol, and a heterogeneous catalyst of formula (I) or formula (II): wherein R′, R″ and R′″ are each H, (C 1 -C 8 )alkyl, (C 6 -C 9 )aryl, or (alk) 3 Si, wherein each alk is (C 1 -C 4 )alkyl; L is an organic linking moiety and X is a solid support material, and the salts thereof under conditions wherein the catalyst catalyzes the formation of the (C 1 -C 3 ) ester of the acid portion of the ester and the corresponding free alcohol of the ester.

  本发明提供了一种酯的酯交换方法，包括将酯、一种C1-C3醇和具有式(I)或式(II)的非均相催化剂结合在一起： 其中R′、R″和R′″分别为H、(C1-C8)烷基、(C6-C9)芳基或(烷)3Si，其中每个烷基为(C1-C4)烷基；L为有机连接基团，X为固体支撑材料，以及它们的盐，在催化剂催化的条件下，催化剂催化酯的酸部分和酯的相应游离醇的(C1-C3)酯的形成。
• [EN] PROCESS FOR PREPARING APIXABAN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE L'APIXABAN
  申请人：KRKA D D NOVO MESTO

  公开号：WO2020120485A1

  公开（公告）日：2020-06-18

  The present invention relates to process for preparing apixaban, in particular polymorphic form N-1 thereof, as well as to a method for the preparation of crystalline apixaban, especially apixaban polymorphic form N-1.

  本发明涉及制备阿匹沙班的方法，特别是其N-1多形态形式，以及制备结晶阿匹沙班的方法，特别是阿匹沙班的N-1多形态形式。